Review the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.
Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.
With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.
Gain expert perspectives on the latest data on the management of atopic dermatitis from the 2020 AAAAI, AAD, and RAD conferences.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.